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The identification of intracellular signaling pathways that promote cell proliferation and resistance to cell death
may lead to the development of improved treatment for advancedmelanoma. Here we show that the calcineurin/
nuclear factor of activated T cells c2 (NFATc2) pathway has an antiapoptotic role in melanoma cells. Expression
of NFATc2 was constitutive in vitro and in vivo in human melanoma, and cyclosporin A (CsA) treatment of
melanoma cells led to downmodulation of NFATc2. Inhibition of the calcineurin/NFAT pathway by CsA, or by
NFATc2 silencing, led to modulation of cell cycle inhibitors and apoptosis-related proteins such as Apollon, and
promoted caspase-dependent apoptosis of neoplastic cells. Calcineurin/NFATc2 targeting significantly enhanced
melanoma cell death induced by antitumor agents, such as MEK- or BRAFV600E-specific inhibitors, and tumor
necrosis factor–related apoptosis-inducing ligand, which trigger the intrinsic or extrinsic pathway of apoptosis,
respectively. These findings identify NFATc2 as a potential therapeutic target in melanoma.
Journal of Investigative Dermatology (2012) 132, 2652–2660; doi:10.1038/jid.2012.179; published online 21 June 2012
INTRODUCTION
Advanced melanoma is an aggressive disease, resistant to
conventional therapies, and median survival for American Joint
Committee on Cancer stage IV patients iso1 year (Garbe et al.,
2011). In most melanomas, the constitutive activation of
different intracellular signaling pathways, such as the mitogen-
activated protein kinase (MAPK) and phosphoinositide-3-kinase/
mammalian target of rapamycin cascades, fuels proliferation and
acquired resistance to programmed cell death (Hocker et al.,
2008). These mechanisms contribute to explain the low
response rates to chemotherapy (Garbe et al., 2011), and the
limited efficacy of biochemotherapy regimens (Eton et al., 2002).
Targeting of constitutively active intracellular signaling pathways
is one of the main strategies to develop effective treatments for
advanced melanoma. The efficacy of this approach is shown by
the significant clinical results obtained with the BRAFV600E-
specific inhibitor Vemurafenib (Chapman et al., 2011). How-
ever, a fraction of patients with BRAFV600E mutant tumors do not
benefit from this treatment (Chapman et al., 2011), and several
mechanisms of acquired resistance have been identified
(Poulikakos and Rosen, 2011). Thus, the identification of new
signaling pathways, with relevant function in melanoma
proliferation and resistance to apoptosis, is urgently needed
and could lead to the definition of new therapeutic targets.
One of these potentially relevant pathways is the
canonical Ca2þ /calcineurin–nuclear factor of activated T cells
(NFAT) signaling cascade (Medyouf and Ghysadel, 2008;
Mancini and Toker, 2009). Signaling from members of the
NFAT family of transcription factors, which in humans
comprises five gene products (NFAT1–5), is thought to
contribute to several aspects of tumor biology, including
growth, survival, invasion, and angiogenesis (Mancini and
Toker, 2009). The interest for this pathway in melanoma stems
from several lines of evidence. First, melanoma cells have a
functional Ca2þ -dependent signaling system (Allen et al.,
1997; Deli et al., 2007). Second, melanoma cells express
different members of the Ca2þ /calcineurin-regulated NFAT
family of transcription factors, and at least some of them are
transcriptionally active (Lockart et al., 2009). Third, inhibition
of the canonical NFAT pathway, by the calcineurin inhibitor
cyclosporin A (CsA), can promote apoptosis of melanoma
cells (Ciechomska et al., 2005), as it occurs in other solid
tumors and hematological malignancies (Ito et al., 1998;
Eckstein et al., 2005). Fourth, CsA has been used with
manageable toxicity in the treatment of metastatic melanoma
patients in association with IFN-a and IL-2 (Feun et al., 2005).
In this study, we investigated the role of the Calcineurin/
NFAT pathway in melanoma cell survival. We found that
this pathway is a potential therapeutic target in melanoma.
In fact, calcineurin inhibition, or targeting of NFATc2/
NFAT1, induced caspase-dependent melanoma cell death.
In addition, calcineurin/NFATc2 targeting significantly
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enhanced the antitumor effects of target-specific drugs, such
as MAPK/extracellular signal–regulated kinase kinase (MEK)
or BRAFV600E inhibitors, and of agents that activate the
extrinsic pathway of apoptosis, such as TRAIL.
RESULTS
Pharmacological inhibition of calcineurin promotes melanoma
cell death
The canonical calcineurin/NFAT pathway can be inhibited
by CsA. Susceptibility of human melanoma cells to the
antiproliferative effects of the calcineurin inhibitor CsA was
assessed by the 3-(4,5) dimethylthiazol-2,5-diphenyltetrazo-
lium bromide assay in a large panel (n¼37) of cell lines with
known BRAF and NRAS mutational status. The inhibitory
effects of CsA were dose dependent, with most tumors
showing 450% inhibition at (CsA) 48 mM (data not shown).
At 96–120 hours, the mean IC50s were in the low micromolar
range for all tumors, independently of serum concentration (4
vs. 8%, Figure 1a). Melanoma susceptibility to CsA was not
significantly different in tumors bearing mutated or wild-type (wt)
BRAF or NRAS oncogenes (P40.05 for all comparisons, by
analysis of variance followed by Student-Newman–Keuls test,
Figure 1a), or wt vs. mutant p53 (Figure 1a). Cell cycle
analysis of CsA-treated melanoma cells indicated a moderate
and dose-dependent reduction of fraction of cells in S and
G2M phases, already detectable at 48 hours (Figure 1b), but a
strong increase in sub-G1 phase at high CsA doses and at
72 hours (Figure 1c), suggesting induction of apoptosis as the
main antitumor effect of CsA. In agreement, assessment of
apoptosis by staining for propidium iodide (PI) vs. Annexin-V
showed a dose-dependent induction of late apoptosis by CsA,
as indicated by the fraction of PIþAnnexin-Vþ cells, at
96–120 hours (see Figure 1d and Supplementary Table S1
online for results from all 37 cell lines grouped according to
BRAF/NRAS mutations).
Melanoma cells express NFATc1 and NFATc2 in vitro and
in vivo, and CsA treatment downregulates NFATc2
The expression of two members of the NFAT family of
transcription factors (NFATc1/NFAT2 and NFATc2/NFAT1)
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Figure 1. Antiproliferative and proapoptotic effects of CsA on human melanoma cells. (a) IC50s (mM) of CsA, by 3-(4,5) dimethylthiazol-2,5-diphenyltetrazolium
bromide assay, on 37 melanoma cells lines with mutant or wild-type (WT) BRAF and NRAS. Black symbols, tumors with mutant p53; empty symbols,
tumors with p53wt. (b) Cell cycle analysis, at 48 hours, of melanoma cells (Me#21158) cultured with/without CsA. Numbers in each panel indicate % of cells
in (left to right) sub-G1, G1, S, and G2M phases of the cell cycle. (c) Cell cycle analysis of CsA-treated Me#21158 melanoma cells at 24, 48, and 72hours.
(d) Annexin-V/propidium iodide stainings of CsA-treated melanoma cells. CsA, cyclosporin A; FCS, fetal calf serum.
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was investigated in vitro and in vivo in melanoma cells. By
flow cytometry analysis in permeabilized cells from a large
panel of melanoma cell lines, NFATc2 and NFATc1 were
found to be constitutively expressed in most of them, although
with a wide range of fluorescence intensity (Figure 2a). By
immunohistochemistry in tissue sections from melanoma
lesions, expression of NFATc2 in neoplastic cells was
confirmed in vivo as well, with nuclear and, sometimes,
cytoplasmic staining (Figure 2b, middle and right panels),
whereas NFATc1 was mostly found in lymphocytes surround-
ing the tumor (Figure 2b, left panel). In vitro, in cell lines,
NFATc1 and NFATc2, when expressed, were mainly found in
the nuclear fraction of neoplastic cells rather than in the
cytoplasm, independently of their culture in the presence/
absence of serum (Figure 2c).
CsA treatment of melanoma cells led to strong down-
regulation of NFATc2 protein expression after 48hours. This
was shown by both western blot (Figure 2d) and flow
cytometry analyses in permeabilized cells (see Figure 2e and
Supplementary Table S1 online for results of 37 cell lines). The
reduced NFATc2 expression, after CsA treatment, was
confirmed by western blot analysis in both nuclear and
cytoplasmic fractions (data not shown). CsA treatment did not
reduce expression of HLA class I molecules (Figure 2e), nor of
NFATc1 (data not shown). Moreover, NFATc2 downregula-
tion, induced by CsA, was prevented by treating melanoma
cells with the pancaspase inhibitor z-VAD-fmk (Supplemen-
tary Figure S1 online), which is in agreement with the
described role of caspases in NFATc2 degradation (Wu
et al., 2006).
NFATc2 silencing, or its pharmacological inhibition, promotes
melanoma apoptosis
To directly assess the role of NFATc2 in melanoma survival,
we carried out silencing experiments by small interfering
RNA (siRNA). Silencing of NFATc2 was achieved with similar
results in 15 different melanoma cell lines from BRAFV600E,
NRASQ61R, or BRAFwt/NRASwt tumors by using three different
Stealth RNAi siRNA oligos (data not shown), and one of them
(Stealth siRNA #11) was chosen for all subsequent experi-
ments. NFATc2 protein levels were strongly reduced at
48 hours (Figure 3a–c) and up to 96 hours (Figure 3a). NFATc2
silencing was effective in all BRAFV600E mutant tumors tested
(Figure 3a and c), as well as in NRASQ61R and BRAFwt/
NRASwt cell lines (data not shown). Inhibition of NFATc2
in melanoma cells led to suppression of IL-6 and GM-CSF
production (Figure 3d), two known transcriptional targets of
NFATc2 (Luo et al., 1996; Weigmann et al., 2008), thus
supporting the notion that NFATc2 is functional in melanoma
cells. No significant effect was seen on other unrelated
molecules, such as CCL4 and CCL15 (Figure 3d). Cell cycle
analysis showed that the most relevant effect of NFATc2
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Figure 2. NFATc1 and NFATc2 expression in melanoma cells and NFATc2 inhibition by CsA treatment. (a) NFATc2 and NFATc1 expression by flow cytometry
in melanoma cell lines (n¼ 37 for NFATc2 and n¼ 18 for NFATc1). (b) NFATc1 and NFATc2 expression by immunohistochemistry in a lymph node metastasis
from a melanoma patient. Right panels, two fields showing NFATc2 expression in nuclei and cytoplasm of neoplastic cells (upper panel) and in tumor-associated
lymphocytes (lower panel). Bar¼ 50mm (c) Expression of NFATc1 and NFATc2 in nuclear (N) and cytoplasmic (C) fractions of melanoma cell lines cultured O/N
with (þ ) or without () FCS (4%). (d) NFATc2 expression by western blot in melanoma cell lines treated with or without CsA (10 mM) for 48 hours. (e) NFATc2
and HLA class I antigen expression (after staining with w6/32mAb, Parham et al., 1979) by flow cytometry in melanoma cells treated with or without CsA
(10mM) for 48 hours. Gray histogram, staining with secondary antibody only. CsA, cyclosporin A; Ctrl, control; FCS, fetal calf serum; MFI, mean fluorescence
intensity; n.d., not done; NFATc2, nuclear factor of activated T cells c2; siRNA, small interfering RNA; WT, wild type.
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silencing was a large increase in the fraction of cells in sub-
G1 phase at 120 hours in comparison with cells transfected
with control siRNA (Figure 3e), consistent with apoptosis
induction. Annexin-V–PI staining assay confirmed that
NFATc2 silencing was associated with promotion of mela-
noma late apoptosis at both 96 and 120hours (Figure 3f).
Such effect was confirmed in 14 different melanoma cell lines
irrespective of BRAF or NRAS mutations (Table S2, column
1). Moreover, treatment with the inhibitor AM404, which
inhibits DNA binding and transcriptional activity of NFATc2
(Caballero et al., 2007), led to melanoma cell apoptosis
(Supplementary Figure S2 online).
In addition, CsA treatment and NFATc2 silencing induced
remarkably similar effects on the expression of apoptosis-
and cell cycle–related proteins. This was documented by
inhibition of antiapoptotic proteins Bcl-2 and survivin and
upregulation of the proapoptotic Bcl-2 family member Bax, of
TRAIL-R2, and of the cell cycle inhibitor p21 (Supplementary
Figure S3 online).
CsA or NFATc2 silencing activates caspase-dependent apoptosis
and downmodulates the IAP Apollon
CsA treatment and NFATc2 silencing led to activation of
caspase-2 (see Figure 4a and b, and Supplementary Table S2
online, columns 2–5 for results from 14 cell lines) and
caspase-3 (Figure 4a and b). The pancaspase inhibitor z-VAD-
fmk, but not the negative control z-FA-fmk, significantly
inhibited caspase-2 and -3 activation, promoted by CsA
treatment and NFATc2 silencing (Figure 4a and b). The same
pancaspase inhibitor z-VAD-fmk also strongly suppressed
melanoma apoptosis induced by either CsA or NFATc2
silencing (Figure 4c and d). In addition, the caspase-2-specific
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inhibitor z-VDVAD-fmk inhibited CsA- and NFATc2 silen-
cing–dependent apoptosis (Supplementary Figure S4 online).
Caspase-2 is activated by several stimuli (Kumar, 2009)
and also upon deletion of the inhibitor of apoptosis protein
(IAP) Apollon (Ren et al., 2005). We therefore tested whether
CsA treatment or NFATc2 silencing could modulate the
expression of this IAP. By performing western blot and flow
cytometry analyses in permeabilized cells, we found that
Apollon was constitutively expressed in different melanomas
bearing either mutant or wt BRAF and NRAS oncogenes
(Figure 5a and b). Apollon expression was strongly inhibited
by CsA treatment, as determined by western blot (Figure 5a)
and flow cytometry analyses in permeabilized cells from
different tumors (see Figure 5b and Supplementary Table S1
online for results from 37 cell lines). Apollon expression was
reduced not only after CsA treatment but also even upon
NFATc2 silencing (see Figure 5c and d for western blot and
flow cytometry results, respectively). Other IAPs such as
c-IAP1, c-IAP2, XIAP, and Livin were not significantly
modulated at the protein level by either CsA treatment or
NFATc2 silencing (Supplementary Figure S5 online). Upon
CsA treatment or NFATc2 silencing, Apollon downregulation
was associated with p53 stabilization in p53wt melanoma
cells (Figure 5c). CsA treatment led to Apollon down-
modulation even in p53-mutant tumors (Figure 5d, rightmost
panel). Reduced expression of Apollon protein was observed
even by treating melanoma cells with the NFATc2 inhibitor
AM404 (Figure 5e).
Taken together, these results suggest that inhibition of the
calcineurin/NFATc2 pathway leads to downregulation of
Apollon associated with caspase activation and enhanced
melanoma apoptosis.
Calcineurin/NFATc2 targeting enhances the antitumor effects
of MEK or BRAFV600E inhibitors, and of TRAIL
The association of low-dose (1mM) CsA with the MEK inhibitor
PD0325901, the BRAFV600E inhibitor PLX4720 (in BRAFV600E-
mutant tumors), or with TRAIL significantly enhanced
apoptosis in 17 different melanoma cell lines including
p53-mutant tumors (Me#14362 and Me#2211, Supplementary
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units; siRNA, small interfering RNA. ***Po0.001.
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Table S3 online) compared with treatments without CsA.
Melanoma apoptosis was significantly enhanced even by
association of the NFATc2 inhibitor AM404 with PD0325901,
or PLX4720, or TRAIL (Supplementary Figure S6 online).
Mechanistically, the association of low-dose CsA with
these antitumor agents significantly enhanced modulation of
Bax, of the cell cycle inhibitors p21 and p27, of TRAILR2, and
of FADD adapter (Supplementary Figure S7a online). The
combined treatments led to a significant increase of caspase-2
and -3 activation compared with treatments without CsA
(Supplementary Figure S7b online). Similarly, the combination
CsAþ TRAIL significantly enhanced activation of caspase-8
(Supplementary Figure S7c online). Finally, association of
low-dose CsA with PD0325901, PLX4720, or TRAIL markedly
inhibited Apollon expression, compared with treatments
without CsA (Supplementary Figure S7d online).
Taken together, these results provide the rationale for
targeting the calcineurin/NFATc2 pathway in association
with other antitumor agents that promote melanoma cell
death by the intrinsic or extrinsic apoptosis pathways.
DISCUSSION
Pharmacological inhibition of calcineurin, with CsA, as well
as NFATc2 silencing, and/or NFATc2 inhibition by AM404,
promoted melanoma cell death associated with activation of
caspase-2 and caspase-3. Melanoma apoptosis triggered by
CsA, or NFATc2 silencing, was inhibited by a pancaspase
inhibitor and by a caspase-2-specific inhibitor, suggesting
that the calcineurin/NFATc2 pathway has a prosurvival
function in melanoma cells and that its inhibition activates
caspase-dependent apoptosis.
A direct antiapoptotic role of NFATc2, as reported here,
has not been previously found in any tumor type, although
calcineurin inhibition has been shown to induce apoptosis
and caspase activation in melanoma and other tumors (Ito
et al., 1998; Ciechomska et al., 2005; Eckstein et al., 2005;
Sato et al., 2011). In addition, current evidence indicates that
different members of the NFAT family may promote tumor
proliferation rather than inhibiting apoptosis. In pancreatic
adenocarcinoma cells, a different NFAT family member
(NFATc1/NFAT2) has been shown to stimulate cell prolifera-
tion by activating c-myc transcription (Ko¨enig et al., 2010),
and NFATc1 silencing led to the inhibition of cell cycle
progression and not to apoptosis. In pancreatic and colon
cancer cell lines, silencing of NFATc2 or NFATc1 prevents
upregulation of cell cycle regulators cyclin D1 and D4, as
well as of the cell cycle kinases CDK4 and 6, induced by
TGF-b (Singh et al., 2010). In melanoma cells, evidence
consistent with a potential role of other NFAT family
members (NFAT2/NFATc1 and NFAT4) in tumor growth has
been achieved by silencing experiments showing that these
two transcription factors can directly regulate COX-2 expres-
sion (Lockart et al., 2009), and COX2-derived bioactive lipids
promote tumor growth (Mann et al., 2005). However, in
normal cardiomyocytes, a peptide that inhibits calcineurin
binding to multiple NFAT members has been shown to
induce apoptosis after phenylephrine stimulation (Pu et al.,
2003). In pancreatic b cells, the calcineurin inhibitor
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Figure 5. Calcineurin inhibition or NFATc2 silencing downregulates the expression of the antiapoptotic protein Apollon. (a, b) Apollon expression by western
blot (a) or flow cytometry (b) analyses in melanoma cell lines treated with or without CsA (10 mM, 48 hours). (c) Apollon and p53 expression by western blot
analysis in Me#2934 cells treated with or without CsA (10 mM, 48 hours) or transfected with control- or NFATc2-specific siRNA (72 hours). (d) Apollon expression
in Me# 2934 cells (left and middle panels) or in p53-mutant Me#14362 cells (right panel), by flow cytometry, after CsA treatment or NFATc2 silencing.
(e) Apollon expression by flow cytometry in Me#21158 melanoma cells treated with or without the NFATc2 inhibitor AM404 (10mM, 72 hours). Gray histograms
in b, d, and e indicate cells stained with secondary antibody only. CsA, cyclosporin A; Ctrl, control; n.d., not done; NFATc2, nuclear factor of activated T cells
c2; siRNA, small interfering RNA; WT, wild type.
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tacrolimus promotes apoptosis by reduction of NFATc1
binding to the Irs2 promoter (Soleimanpour et al., 2010).
Melanoma apoptosis, by inhibition of the calcineurin/
NFATc2 pathway, was associated with Apollon protein
downregulation. NFATc2 silencing did not lead to inhibition
of Apollon gene expression (data not shown), but lactacystin
treatment suppressed CsA-induced Apollon downregulation
(data not shown), suggesting that Apollon may undergo
proteasome-dependent degradation upon inhibition of the
CsA/NFAT pathway. Apollon downmodulation can contri-
bute to activate caspase-2-dependent apoptosis (Ren et al.,
2005), and caspase-2 has been shown to have a role in
promoting expression of the cell cycle inhibitor p21, in DNA-
damage response (Sohn et al., 2011), and in inhibition of
survivin expression (Guha et al., 2010). This may explain the
changes in p21 and survivin that we observed following
calcineurin/NFATc2 inhibition.
Apoptosis, associated with Apollon downmodulation, by
CsA treatment was observed even in melanoma cells
bearing mutant p53. Interestingly, enhanced cell death after
Apollon silencing has been described in breast cancer cells
bearing mutant p53 (Lopergolo et al., 2009). This suggests
that downregulation of Apollon can promote caspase
activation and apoptosis, by either a p53-dependent pathway
(in p53-proficient cells) or a p53-independent pathway
(in p53-deficient cells). Interestingly, caspase-2 activation
may occur not only through the p53-regulated PIDDosome
molecular platform, but also even in the absence of PIDD and
in response to p53-independent stress signals (Manzl et al.,
2009).
Combination of calcineurin/NFATc2 inhibition with MEK-
or BRAFV600E-specific inhibitors or TRAIL markedly enhanced
melanoma cell apoptosis, thus corroborating the potential
role of the calcineurin/NFATc2 pathway as a therapeutic
target, as found in preclinical models of tumors other
than melanoma (Gregory et al., 2010; Han et al., 2010). In
conclusion, the results of this study indicate that targeting of
the calcineurin/NFATc2 pathway may activate caspase-
dependent apoptosis of human melanoma cells and can
significantly enhance the proapoptotic effects of other
antitumor agents that trigger the intrinsic or extrinsic pathway
of programmed cell death.
MATERIALS AND METHODS
Melanoma cell lines and reagents
Melanoma cell lines used in this study were established as described
(Daniotti et al., 2004; Anichini et al., 2006) from surgical specimens
of American Joint Committee on Cancer Stage IIIc and IV melanoma
patients not previously subjected to chemotherapy. The study was
conducted according to the Declaration of Helsinki Principles, and
institutional approval for experiments was not required. Written
informed consent was obtained from patients. Molecular and
biological characterization of the cell lines and methods for
identification of mutations in BRAF, NRAS, and p53 genes have
been reported previously (Daniotti et al., 2004; Petti et al., 2006;
Sensi et al., 2006). All cell lines were maintained as described
(Anichini et al., 2006). Primary and secondary antibodies used are
listed in Supplementary Methods Table S4 online.
Treatment of melanoma cells with CsA, signaling pathway
inhibitors, or TRAIL
CsA (Sigma-Aldrich, St Louis, MO) was used at a concentration of
1–10mM. In some experiments, cells were also treated with the MEK
inhibitor PD0325901 (Cayman Chemical Company, Ann Arbor, MI),
at 1.5nMl1, or the BRAFV600E-specific inhibitor PLX4720 (Selleck
Chemicals, Houston, TX) at 0.25mMl1, or recombinant TRAIL (Alexis
Biochemicals, Enzo Life Sciences, Exeter, UK) at 80ngml1, with/
without CsA. The NFATc2 inhibitor AM404 (Enzo Life Sciences) was
used at a concentration of 10–50mM. Cultures were then evaluated at
48 to 120hours for proliferation, by the 3-(4,5)dimethylthiazol-2,5-
diphenyltetrazolium bromide assay, for cell cycle phases by flow
cytometry after staining with PI, and for apoptosis by the Annexin-V/
PI assay, as described (Zanon et al., 2004; Petti et al., 2006; Sensi
et al., 2006). Expression of intracellular molecules was evaluated by
flow cytometry after melanoma cell permeabilization with saponin or
methanol, as described (Anichini et al., 2006; Mortarini et al., 2009).
Results were expressed as mean fluorescence intensity after subtrac-
tion of mean fluorescence intensity in cells stained with secondary
antibody only. Flow cytometry experiments were carried out
with a FACSCalibur flow cytometer (BD Biosciences, San Diego,
CA). Cell cycle phases were evaluated by the FlowJo software
(Tree Star, Ashland, OR).
Western blots
SDS-PAGE was performed using 30 mg of protein samples on 3–8%
NuPAGE Tris-Acetate (Invitrogen Life Technologies, Camarillo, CA)
as described (Sensi et al., 2006). Development was performed by the
chemiluminescence method with the ECL Plus Western Blotting
Detection System (GE Healthcare, Little Chalfont, UK). Western Blot
analysis for nuclear and cytoplasmic proteins was carried out as
described in Supplementary methods online.
Immunohistochemistry
Immunohistochemistry was performed with formalin-fixed, paraffin-
embedded tissues as described (Anichini et al., 2006). Images
were acquired at  20 with an Axiovert 100 microscope (Zeiss, Carl
Zeiss, Thornwood, NY) equipped with a digital camera (AxioCam
MrC5, Zeiss).
NFATc2 knockdown
Three Stealth Select RNAi siRNA oligos (Oligo ID: HSS107110,
HSS107111, HSS107112) specific for NFATc2 (#1299003 Invitrogen
Life Technologies) and corresponding recommended Stealth RNAi
siRNA Negative Controls (HiGC, #12935-400, LoGC #12935-200,
MedGC #12935-300, respectively) were used. One of the oligos
(ID:HSS107111, sequence 50-UCUACGUCAUCAAUGGGAAGAGA
AA-30) was selected and used for all experiments (100nM final concen-
tration) according to Lipofectamine RNAiMAX guidelines (Invitrogen,
Grand Island, NY).
Detection of caspase activity and caspase inhibitors
Enzymatic activity of caspase-2, -3, and -8 on 50 mg per well of cell
lysate was assessed by the Caspase-2/ICH-1, Apopcyto/Caspase-3,
and Apopcyto/Caspase-8 Fluorometric Assay Kits (Medical and
Biological Laboratories, Naka-ku Nagoya, Japan) with the TECAN
Infinite M1000 (Tecan Group, Mannedorf, Switzerland). In some
experiments, melanoma cells were preincubated with the general
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caspase inhibitor z-VAD-fmk (BD Pharmingen, San Diego, CA) or
the caspase-2-specific inhibitor (Caspase-2 Inhibitor I, z-VD(OMe)-
VAD(OMe)-fmk, Calbiochem, Merck, KGaA, Darmstadt, Germany)
or control z-FA-fmk (BD Pharmingen) at 10 mmol l1 for 1 hour at
371C before further treatments.
Apoptosis and cytokine protein arrays
The Human Apoptosis Array Kit (R&D Systems, Minneapolis, MN)
and RayBio Human Cytokine Antibody Array 5 (RayBiotech,
Norcross, GA) were used to evaluate the expression levels of 35
apoptosis-related proteins in the cell lysates, or of 80 cytokines in
culture supernatants, respectively. The signals on membranes were
detected by the chemiluminescence method following the manu-
facturer’s protocol (Amersham Biosciences, Piscataway, NJ). The
intensity of protein signals was quantified by densitometric analysis
with the Quantity One software (BioRad Laboratories, Hercules,
CA). After background subtraction, results were expressed as the
percentage of the mean of the relative positive controls.
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